CytomX Therapeutics, Inc. (CTMX) has 139 open-market insider trades by 23 insiders since 2015. Over the last six months insiders net sold $5K. The most active filer is Sean A. McCarthy, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| TRV Gp, LLC | 10% Owner | — | 1 | $28.7M | 2017-07-13 |
| Timothy M. Shannon | Dir | — | 17 | $13.8M | 2016-11-29 |
| Sean A. McCarthy | CEO | — | 35 | $9.0M | 2026-03-17 |
| James E. Flynn | 10% | — | 1 | $7.5M | 2015-10-14 |
| Canaan IX L.P. | Dir10% Owner | — | 11 | $6.1M | 2017-03-27 |
| Canaan Partners IX LLC | Dir | — | 9 | $3.3M | 2016-11-30 |
| Debanjan Ray | CFO | — | 14 | $2.7M | 2018-12-12 |
| Frederick W. Gluck | Dir | — | 9 | $1.7M | 2019-04-08 |
| William Michael Kavanaugh | CSO | — | 2 | $1.2M | 2017-12-08 |
| Robert I. Tepper | 10% Owner | — | 3 | $1.2M | 2017-10-04 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Christopher Ogden | CFO | Sell | $5K | 2026-06-15 |
| Christopher Ogden | CFO | Sell | $248K | 2026-03-17 |
| Marcia Belvin | CSO & VP | Sell | $404K | 2026-03-17 |
| Yu-Waye Chu | — | Sell | $273K | 2026-03-17 |
| Sean A. McCarthy | CEO | Sell | $1.5M | 2026-03-17 |
| Sean A. McCarthy | CEO | Sell | $462K | 2025-11-06 |
Companies that share insiders with CTMX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Sean A. McCarthy | CEO | Sell | $924K | 2025-11-06 |
| Marcia Belvin | SVP & Chief Scientific Officer | Sell | $37K | 2025-06-16 |
| Sean A. McCarthy | CEO | Sell | $299K | 2025-06-16 |
| Christopher Ogden | CFO | Sell | $33K | 2025-06-13 |
| Yu-Waye Chu | Chief Medical Officer | Sell | $2K | 2025-03-18 |
| Sean A. McCarthy | CEO | Sell | $23K | 2025-03-18 |
| Marcia Belvin | SVP & Chief Scientific Officer | Sell | $12K | 2025-03-18 |
| Christopher Ogden | CFO | Sell | $5K | 2025-03-18 |
| Lloyd A. Rowland | General Counsel | Sell | $6K | 2025-03-18 |